Interaction of nonsteroidal anti-inflammatory drugs (NSAID) with Helicobacter pylori in the stomach of humans and experimental animals

Journal of Physiology and Pharmacology

Volumn 57, Issue SUPPL. 3, 2006, Pages 67-79

  Brzozowski, T ^a   Konturek, P C ^b   Sliwowski Z ^a   Kwiecien S ^a   Drozdowicz, D ^a   Pawlik, M ^a   Mach, K ^a   Konturek, S J ^a   Pawlik, W W ^a  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Aspirin; Cyclooxygenase; Gastric adaptation; Helicobacter pylori; Nonsteroidal anti inflammatory drugs; Peptic ulcer

Indexed keywords

ACETYLSALICYLIC ACID; AMOXICILLIN; ANTIBIOTIC AGENT; CLARITHROMYCIN; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; GROWTH FACTOR; NONSTEROID ANTIINFLAMMATORY AGENT; OMEPRAZOLE; PLACEBO; PROSTAGLANDIN E2; PROTON PUMP INHIBITOR; TRANSFORMING GROWTH FACTOR ALPHA; VASCULOTROPIN;

BACTERIAL INFECTION; BLOOD VESSEL INJURY; CLINICAL TRIAL; DUODENUM ULCER; DYSPEPSIA; ENZYME ACTIVITY; EXTRAVASATION; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HELICOBACTER PYLORI; HUMAN; META ANALYSIS; MUCOSA ASSOCIATED LYMPHOID TISSUE LYMPHOMA; NONHUMAN; PATHOPHYSIOLOGY; PEPTIC ULCER; PEPTIC ULCER BLEEDING; PROTEIN EXPRESSION; REVIEW; RISK FACTOR; STOMACH ACID SECRETION; STOMACH BLOOD FLOW; STOMACH CANCER; STOMACH EROSION; STOMACH HEMORRHAGE; STOMACH MUCOSA; STOMACH MUCOSA LESION; STOMACH ULCER; SYSTEMATIC REVIEW; ULCER HEALING; ULCEROGENESIS;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTI-ULCER AGENTS; GASTRIC MUCOSA; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; PEPTIC ULCER; STOMACH;

EID: 33750309446     PISSN: 08675910     EISSN: 08675910     Source Type: Journal    
DOI: None     Document Type: Review

References (44)

1. Wallace JL. Nonsteroidal anti-inflammatory drugs and gastroenteropathy: the second hundred years. Gastroenterology 1997; 112: 1000-1016.
2. Rainsford KD. The ever-emerging anti-inflammatories. Have there been any real advances? J Physiol (Paris) 2001; 95: 11-19.
3. McCarthy DM. Prevention and treatment of gastrointestinal symptoms and complications due to NSAIDs. Best Pract Res Clin Gastroenterol 2001; 15: 755-773.
4. Laine L. Approaches to nonsteroidal anti-inflammatory drugs use in the high-risk patient. Gastroenterology 2001; 120: 594-606.
5. Wang JY, Yamasaki S, Takeuchi K, Okabe S. Delayed healing of acetic acid- induced gastric ulcers in rats by indomethacin. Gastroenterology 1989; 96: 393-402.
6. Brzozowski T. Experimental production of peptic ulcer, gastric damage and cancer models and their use i pathophysiological studies and pharmacological treatment - Polish achievements. J Physiol Pharmacol 2003; 54 (Suppl 3): 99-126.
7. Penney AG, Andrews FJ, O B'rien PE. Effects of misoprostol on delayed ulcer healing induced by aspirin. Dig Dis. Sci 1994; 39: 934-939.
8. Hirose H, Takeuchi K, Okabe S. Effect of indomethacin on gastric mucosal blood flow around acetic acid-induced gastric ulcers in rats. Gastroenterology 1991; 100: 1259-1265.
9. Silverstein FE, Graham DY, Senior JR, et al. Misoprostol reduces serious gastrointestinal complications in patients with rheumatoid arthritis receiving nonsteroidal anti-inflammatory drugs. A randomized, double-blind placebo-controlled trial. Ann Intern Med 1995; 123: 241-249.
10. Konturek SJ, Konturek PC, Brzozowski T, Konturek JW, Pawlik WW. From nerves and hormones to bacteria in the stomach: Nobel Prize for achievements in gastroenterology during last century. J Physiol Pharmacol 2005; 56 (4): 507-530.
11. Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 wk of rofecoxib, naproxen or placebo: a multicentre, randomized, double blind study. Gut 2003; 52: 820-826.
12. Chan FKL. Helicobacter pylori, NSAIDs and gastrointestinal hemorrhage. Eur J Gastroenterol Hepatol 2002; 14: 1-3.
13. Tytgat GNJ. Ulcers and gastritis. Endoscopy 2000; 32: 108-117.
14. Fendrick AM, Scheiman JM. Helicobacter pylori and NSAID gastropathy: an ambiguous association. Curr Rheumatol Rep 2001; 1 3(2): 107-111.
15. Chan FKL, Sung, JJ, Chung, SC, et all. Randomized trial of eradication of H. pylori before nonsteroidal anti-inflammatory drug therapy to prevent peptic ulcers. Lancet 1997; 350: 975-979.
16. Huang, J-Q, Sridhar S, Hunt R. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic ulcer disease: a meta-analysis. Lancet 2002; 359: 14-20.
17. Loeb DS, TAlley NJ, Ahlquist DA, Carpenter HA, ZinsmeisterAR. Lg-term nonsteroidal anti-inflammatory drug use and gastroduodenal injury: the role of Helicobacter pylori infection. Gastroenterology 1992; 102: 1899-1905.
18. Pilotto A, Leandro G, Di Mario F, Franceschi M, Bozzola L, Valerio G. Role of Helicobacter pylori infection on upper gastrointestinal bleeding in the erderly:case-control study. Dig Dis Sci 1997; 42: 586-591.
19. Stack WA, Atherton JC, Hawkey GM, Logan RF, Hawkey CJ. Interactions between Helicobacter pylori and other risk factors for peptic ulcer bleeding. Aliment Pharmacol Ther 2002;16: 497-506.
20. Chan FK, Sung, JJ, Suen R, et al. Does eradication of Helicobacter pylori impair healing of nonsteroidal anti-inflammatory drug associated bleeding peptic ulcers? A prospective randomized study. Aliment Pharmacol Ther 1998; 12: 1201-1205.
21. Bianchi Porro G, Parente F, Imbesi V, Montrone F, Caruso I. Role of Helicobacter in ulcer healing and recurrence of gastric and duodenal ulcers in long term NSAID users; response to omeprazole dual therapy. Gut 1999; 39: 22-26.
22. Hawkey CJ, Tulassay Z, Szczepanski L, et al. Randomized controlled trial of Helicobacter pylori eradication in patients on nonsteroidal anti-inflammatory drugs: The HELP NSAIDs study. Helicobacter Eradication for Lesion Prevention. Lancet 1998; 352: 1016-1021.
23. van Herwaarden MA, Samson M, van Nispen CH, Mulder PG, Smouth AJ. The effect of Helicobacter pylori eradication on intragastric pH during dosing with lansoprasole or ranitidine. Aiment Pharmacol Ther 1999; 13: 731-740.
24. Campbell DR, Haber MM, Sheldon E, et al. Effect of H. pylori status on gastric ulcer healing in patients continuing nonsteroidal anti-inflammatory therapy and receiving treatment with lansoprasole or ranitidine. Am J Gastroenterol 2002; 97: 2208-2214.
25. Konturek PC, Brzozowski T, Kwiecien S, et al. Effect of Helicobacter pylori on delay in ulcer healing induced by aspirin in rats. Eur J Pharmacol 2002; 451: 191-202.
26. Tarnawski A. Cellular mechanism of gastric ulcer healing. In The Stomach, Domschke W, Konturek SJ (eds), Berlin: Springer Verlag, 1993, pp.177-192.
27. Konturek PC, Brzozowski T, Konturek SJ, Ernst H, Drozdowicz D, Pajdo R. Expression of epidermal growth factor and transforming growth factor alpha during ulcer healing. Scand J Gastroenterol 1997; 32: 6-15.
28. Szabo S, Vincze A. Growth factors in ulcer healing: lessons from recent studies. J Physiol Paris 2000; 94 (2): 77-81.
29. Coffey RJ, Romano M, Goldenring J. Roles for transforming growth factor-a in the stomach. J Clin Gastroenterol 1995; 21: (Suppl.1): S36-S39.
30. Neufeld G, Tzafra C, Gengrinovitch S, Poltorak Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J.1999; 13: 9-22.
31. Brzozowski T, Konturek PC, Konturek SJ, et al. Effect of local application of growth factors on gastric ulcer healing and mucosal expression of cyclooxygenase-1 and cyclooxygenase-2. Digestion 2001; 64: 15-29.
32. Takahashi M, Maeda S, Ogura K, Terano A, Omata M. The possible role of vascular endothelial growth factor (VEGF) in gastric ulcer healing: effect of sofalcone on VEGF release in vitro. J Clin Gastroenterol 1998; 27 (Suppl 1): S178-S182.
33. Takahashi M, Kawabe T, Ogura K, et al. Expression of vascular endothelial growth factor at the human gastric margin and in cultured gastric fibroblasts: a new angiogenic factor for gastric ulcer healing. Biochem Biophys Res Commun 1997; 234: 493-498.
34. Li H, Mellgard B, Helander H. Inoculation of VacA- and CagA- Helicobacter pylori delays gastric ulcer healing in rat. Scand J Gastroenterol 1997; 32: 439-444.
35. Davies NM, Sharkey KA, Asfaha S, MacNaughton WK, Wallace JL. Aspirin causes rapid upregulation of cyclooxygenase-2 expression in the stomach of the rats. Aliment Pharmacol Ther 1997; 11: 1101-1108.
36. Lanas A. Prevention and treatment of NSAID-induced gastroduodenal injury. Curr Treat Opt Gastroenterol 2006; 9:147-156.
37. Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with Helicobacter pylori infection who are taking low-dose aspirin or naproxen. N Engl J Med 2001; 344: 967-973.
38. Lanas A, Fuentes J, Benito R, Serrano P, Bajador E, Sainz R.Helicobacter pylori increases risk of upper gastrointestinal bleeding in patients taking low-dose aspirin. Aliment Pharmacol Ther 2002; 16: 779-786.
39. Papatheodoris GV, Archimandritis AJ. Role of Helicobacter pylori eradication in aspirin or nonsteroidal anti-inflammatory drugs users. World J Gastroenterol 2005; 11(25): 3811-3816.
40. Konturek PC, Brzozowski T, Konturek SJ, et al. Activation of genes for growth factors and cyclooxygenase in rat gastric mucosa during recovery from stress damage. Eur J Pharmacol 1998; 342: 55-65.
41. Konturek JW, Dembinski A, Konturek SJ, Stachura J, Domschke W. Infection of Helicobacter pylori in gastric adaptation to continued administration of aspirin in humans. Gastroenterology 1998; 114: 245-255.
42. Brzozowski T, Konturek PC, Konturek SJ, Ernst H, Stachura J, Hahn EG. Gastric adaptation to injury by repeated doses of aspirin strengthens mucosal defense against subsequent exposure to various strong irritants in rats. Gut 1995; 37: 749-757.
43. Sousa MHLP, de Lima OM, Zamuner SR, Fiorucci S, Wallace JL. Gastritis increases resistance to aspirin-induced mucosal injury via COX-2-mediated lipoxin synthesis. Am J Physiol 2003; 285: G54-61.
44. Fiorucci S, Distrutti E, de Lima OM, et al. Relative contribution of acetylated cyclooxygenase (COX)-2 and lipoxygenase (LOX) in regulating gastric mucosal integrity and adaptation to aspirin. FASEB J 2003; 17: 1171-1173.